If You Liked Part D, You'll Love Universal Coverage
This article was originally published in RPM Report
Executive Summary
It’s hard to say for sure how big a boost universal coverage would give to pharmaceutical companies’ bottom lines. But the industry’s most recent experience with expanded coverage in the key Medicare market offers some encouraging benchmarks for what to expect.
You may also be interested in...
The Part D Peak: Big Pharma's Blowout Quarter
While many people were watching the Senate grapple with drug price negotiation authority for CMS, Big Pharma blew past Wall Street's expectations with big first quarter gains. One year into the program, Medicare is definitely paying off. But will the party last?
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.
Cost-Based Pricing: The Real Threat Hiding In Latest US Drug Price Headlines
Bernie Sanders is back at it, getting headlines for demanding immediate price cuts to Novo’s blockbuster GLP-1 brands. But behind the familiar rhetoric is a newer threat: academic research on cost-based pricing that could one day feed into the emerging Medicare ‘negotiation’ system.